Nosocomial urinary tract infection in the intensive care unit: When should Pseudomonas aeruginosa be suspected? Experience of the French national surveillance of nosocomial infections in the intensive care unit, Rea-Raisin

Clinical Microbiology and Infection

Volumn 18, Issue 1, 2012, Pages

  Venier, A G ^a,b   Lavigne, T ^c   Jarno, P ^d   L'heriteau, F ^e   Coignard, B ^f   Savey, A ^g   Rogues, A M ^b  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^d RENNES UNIVERSITY HOSPITAL   (France)

^e Pavillon Leriche   (France)

^f InVS   (France)

^g HOSPICES CIVILS DE LYON   (France)

Author keywords

Hospital acquired (nosocomial) infection; Intensive care unit; Pseudomonas aeruginosa; Surveillance; Urinary tract infection

Indexed keywords

AMINOGLYCOSIDE; CEPHALOSPORIN; CIPROFLOXACIN; CORTICOSTEROID; IMIPENEM; LEVOFLOXACIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM;

ANTIMICROBIAL THERAPY; ARTICLE; BACTEREMIA; BACTERIAL COLONIZATION; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; FOREIGN BODY; HOSPITAL ADMISSION; HOSPITAL INFECTION; HUMAN; INFECTION RISK; INTENSIVE CARE UNIT; LENGTH OF STAY; NEUROGENIC BLADDER; PATIENT TRANSPORT; PRIORITY JOURNAL; PROSTATE SURGERY; PSEUDOMONAS AERUGINOSA; RISK FACTOR; URINARY CATHETER; URINARY TRACT INFECTION;

PSEUDOMONAS AERUGINOSA;

EID: 83655201281     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2011.03686.x     Document Type: Article

References (20)

1. Rosenthal VD, Maki DG, Jamulitrat S et al. International Nosocomial Infection Control Consortium (INICC) report, data summary for 2003-2008. Am J Infect Control 2010; 38: 95-104.
2. Agodi A, Auxilia F, Barchitta M et al. Building a benchmark through active surveillance of intensive care unit-acquired infections: the Italian network SPIN-UTI. J Hosp Infect 2010; 74: 258-265.
3. Suetens C, Morales I, Savey A et al. European surveillance of ICU-acquired infections (HELICS-ICU): methods and main results. J Hosp Infect 2007; 65: 171-173.
4. Mittal R, Aggarwal S, Sharma S, Chhibber S, Harjai K. Urinary tract infections caused by Pseudomonas aeruginosa: a minireview. J Infect Public Health 2009; 2: 101-111.
5. Schechner V, Nobre V, Kaye KS et al. Gram-negative bacteraemia upon hospital admission: when should Pseudomonas aeruginosa be suspected? Clin Infec Dis 2009; 48: 580-586.
6. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999; 43: 1379-1382.
7. Desenclos JC; RAISIN Working Group. RAISIN-a national programme for early warning, investigation and surveillance of healthcare-associated infection in France. Euro Surveill 2009; 14: 19408.
8. HELICS-ICU working group. Surveillance of nosocomial infections in intensive care units. Protocol, version 6.1.IPH/EPI reports D/2004/2505/48. Brussels: Scientific institute of Public Health, 2004.
9. Merlo J, Chaix B, Ohlsson H et al. A brief conceptual tutorial of multilevel analysis in social epidemiology: using measures of clustering in multilevel logistic regression to investigate contextual phenomena. J Epidemiol Community Health 2006; 60: 290-297.
10. Tabibian JH, Gornbein J, Heidari A et al. Uropathogens and host characteristics. J Clin Microbiol 2008; 46: 3980-3986.
11. Thuong M, Arvaniti K, Ruimy R et al. Epidemiology of Pseudomonas aeruginosa and risk factors for carriage acquisition in an intensive care unit. J Hosp Infect 2003; 53: 274-282.
12. Olson B, Weinstein RA, Nathan C, Chamberlin W, Kabins SA. Epidemiology of endemic Pseudomonas aeruginosa: why infection control efforts have failed. J Infect Dis 1984; 150: 808-816.
13. Romero Cullerés G, Sugrañes JC, Planells Romeo I, Giménez Pérez M. Characteristics of urinary tract infections in different patient subpopulations and depending on the bladder emptying system. Actas Urol Esp 2010; 34: 251-257.
14. Yu SM, Jeon SS, Kang IS, An HG. Status of nosocomial urinary tract infections in the ICU: molecular epidemiology of imipenem resistant P. aeruginosa. Taehan Kanho Hakhoe Chi 2006; 36: 1204-1214.
15. Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother 2006; 50: 43-48.
16. Miliani K, L'Hériteau F, Lacavé L, Carbonne A, Astagneau P; Antimicrobial Surveillance Network Study Group. Imipenem and ciprofloxacin consumption as factors associated with high incidence rates of resistant Pseudomonas aeruginosa in hospitals in northern France. J Hosp Infect 2011; 77: 343-347.
17. Martínez JA, Delgado E, Martí S et al. Influence of antipseudomonal agents on Pseudomonas aeruginosa colonization and acquisition of resistance in critically ill medical patients. Intensive Care Med 2009; 35: 439-447.
18. Cunningham JB, Kernohan WG, Rush T. Bed occupancy, turnover intervals and MRSA rates in English hospitals. Br J Nurs 2006; 15: 656-660.
19. Vanderpas J, Louis J, Reynders M, Mascart G, Vandenberg O. Mathematical model for the control of nosocomial norovirus. J Hosp Infect 2009; 71: 214-222.
20. Floret N, Bertrand X, Thouverez M, Talon D. Nosocomial infections caused by Pseudomonas aeruginosa: exogenous or endogenous origin of this bacterium? Pathol Biol 2009; 57: 9-12.